Business ❯ Healthcare

Pharmaceutical Industry

Drug Development Drug Pricing Market Trends Drug Manufacturers Market Analysis Manufacturing Market Competition Drug Manufacturing Biopharmaceuticals Pricing Strategies Clinical Trials Regulatory Affairs Rare Diseases Company Operations Regulations Market Dynamics Biotechnology Generic Drugs Pharmaceutical Companies Vaccine Manufacturers Weight Loss Medications Drug Pricing Strategies Active Pharmaceutical Ingredients Government Contracts Public Contracts Direct-to-Consumer Sales Supply Chain Management Product Launches Clinical Research Women’s Health Revenue Growth Retail Pharmacy Marketing Strategies Weight-Loss Drugs Market Contract Research Organizations Contract Manufacturing Weight Loss Treatment Diabetes Medications Market Agreements Corporate Operations Regulatory Changes Profitability Challenges Drug Reimbursement Prescription Drugs Corruption Investigations Company News Export Growth Obesity Treatments Diabetes Treatment Prescription Drug Pricing Drug Companies Drug Prices Acquisitions Corporate Leadership Pharmacy Benefit Managers Kusum Healthcare International Business Specialty Medicines Discount Programs Precision Medicine Medicine Distribution Healthcare Companies Online Platforms Company Performance Investment Rebate Programs Drug Innovation Product Strategy Pricing Market Access Drug Procurement Marketing Trade Agreements CVS Health Direct Sales Market Challenges Generic Medications Specialty Pharmaceuticals Drug Demand Manufacturing in the USA Drug Approval Process Weight-loss Drugs Consumer Services Workplace Culture Data Resources Drug Approval Drug Sales Formulations Product Development Healthcare Ventures Clinical Research Organizations Drug Regulation AI Partnerships Cannabis Production Cancer Treatments Investments Commercial Operations Domestic Market Targeted Therapies

Cardinal Health Beats Profit Estimates but Misses Revenue in Fiscal Q4

Stronger-than-expected full-year guidance plus a $1 billion buyback commitment signal management's confidence in specialty drug demand and cash flow.

Wall Street Unanimously Bullish on Teva as Austedo Fuels Turnaround

Johnson & Johnson Beats Q2 Estimates and Lifts Full‑Year Outlook

Pfizer CFO Dave Denton to Exit and Cecile Guegan Named Interim

Veeva Beats Q1 Estimates and Raises Outlook as It Pushes an AI Pivot

Pacira Presses Shareholders to Back Its Board in Active Proxy Fight

Jury Finds Takeda Liable for Delaying Amitiza Generics, Awards $885 Million

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

Sun Pharma to Buy Organon for $11.75 Billion in All-Cash Deal

Ligand to Buy XOMA Royalty for $739 Million

Sun Pharma Said to Make $13 Billion All-Cash Offer for Organon

CVS Advances Settlement in FTC Insulin Case Seen as Lifting Market Overhang

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

Trump Touts MFN Drug Deals, Urges GOP to Codify Policy at Doral Retreat

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

Cantor Raises Innoviva Target to $32 After Q4 Beat on China XacDuro Builds

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

TrumpRx Debuts With 43 Discounted Brand Drugs as Analyses Flag Cheaper Generics and Limits